Inhale-3 Study Results to be Presented During a 90-Minute Symposium on Saturday, June 22 at the American Diabetes Association's 84th Scientific Sessions

Core Insights - MannKind Corporation announced the presentation of 17-week endpoint results from the INHALE-3 study at the American Diabetes Association's 84th Scientific Sessions on June 22, 2024 [1][2] - The study compares the efficacy and safety of inhaled insulin Afrezza with multiple daily injections (MDI) and insulin pumps in adults with Type 1 diabetes [2] Company Overview - MannKind Corporation focuses on developing and commercializing innovative inhaled therapeutic products for endocrine and orphan lung diseases [3][4] - The company aims to address serious unmet medical needs through its dry-powder formulations and inhalation devices, providing rapid and convenient delivery of medications [4] Study Details - The INHALE-3 study is the largest post-market clinical trial conducted by MannKind in the last decade, with results expected to clarify how inhaled insulin compares to usual care [2] - The symposium will feature various presentations, including study methods, results, and critiques from experts in the field [2]